2 Stocks That Could Capitalize on the GLP-1 Boom
They aren't the most prominent names in the GLP-1 space, but they are worth a second look.
Overview
Demand for GLP-1 drugs has soared in recent years due to breakthroughs in the field. The list of conditions these medicines can treat has evolved and will continue to do so over the next decade or so, sending the market to new heights. Investors don't want to miss out on this. Thankfully, there are many ways to capitalize on the ongoing GLP-1 boom, even beyond buying shares in the current leaders in the field: Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). Let's consider two stocks to buy that could also cash in on this area's rapid growth: CVS Health (NYSE:CVS) and Roche (OTC:RHHBY).
Image source: The Motley Fool.
CVS Health, a leading pharmacy chain, has performed well over the past 18 months. The company is addressing several issues that have plagued its business, including rising medical costs that have squeezed profits and margins in recent years. But CVS Health is posting much-improved financial results. In the second quarter, the company's revenue increased 7.3% year over year to $106.1 billion, while its adjusted earnings per share (EPS) were $2.58, up 42.5% from the year-ago period.
Details
Source
Originally published at www.fool.com.